1. Acknowledgement to Referees

   Acknowledgement to Referees 12 November 2015 Pages: 407 - 408

2. Lanreotide Autogel^® in acromegaly: a guide to its use in the EU

   • Lesley J. Scott
   • Celeste B. Burnesss
   • Susan J. Keam

   Adis Drug Q&A 05 November 2015 Pages: 409 - 416

   

3. Naltrexone ER/bupropion ER in obesity management: a guide to its use

   • Sarah L. Greig
   • Gillian M. Keating

   Adis Drug Q&A 12 October 2015 Pages: 417 - 424

   

4. Azelastine hydrochloride/fluticasone propionate combined in a single nasal spray: a guide to its use in allergic rhinitis

   • Greg L. Plosker
   • Katherine A. Lyseng-Williamson

   Adis Drug Q&A 13 October 2015 Pages: 425 - 432

5. Adjust therapy for restless legs syndrome if symptoms worsen, efficacy is lost or iatrogenic augmentation develops

   • Adis Medical Writers

   Disease Management 15 October 2015 Pages: 433 - 436

   

6. Cellulite: no clear evidence that any type of treatment is effective

   • Adis Medical Writers

   Disease Management 11 September 2015 Pages: 437 - 440

7. First reports of adverse drug reactions in recent weeks

   Drug Reactions and Interactions 26 October 2015 Pages: 441 - 442

8. Preventative strategies may reduce the risk of chronic kidney disease in elderly patients receiving lithium

   • Adis Medical Writers

   Drug Reactions and Interactions 30 September 2015 Pages: 443 - 447

   

9. Evaluation of ophthalmic adverse drug reactions at a tertiary-care hospital

   • Jignesh Patel
   • Mira Desai
   • Samidh Shah

   Original Research Article 07 October 2015 Pages: 448 - 451

   

10. Quantitative and qualitative analysis of prescriptions at a tertiary-care hospital

    • Moutusi Sadhukhan
    • Bhavik Shah
    • Mira Desai

    Original Research Article 16 September 2015 Pages: 452 - 457

    

11. Erratum to: Pazopanib in advanced renal cell carcinoma: a guide to its use in the EU

    • Katherine A. Lyseng-Williamson

    Erratum 09 November 2015 Pages: 458 - 458